# Ironwood Pharmaceuticals, Inc. - Class A (IRWD) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/IRWD
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Aug 2, 2026

Ironwood Pharmaceuticals, Inc. - Class A (IRWD) last closed at $4.23, in the upper half of its 52-week range of $0.72–$5.78. Composite market sentiment across 1 analysis is positive (+19 on a −100 to +100 scale), as of Aug 2, 2026.

## What the data says

At $4.23, the stock sits toward the upper end of a 52-week range that runs from $0.72 to $5.78 — a band in which the high is roughly eight times the low. A spread that wide over a single year points to a stock that has repriced dramatically rather than drifted, and the current price sits close to six times the low while remaining about 27% below the high. Market capitalization is around $696 million, so this remains a small-cap name despite the move.

On the earnings the company currently reports, the market is applying a low multiple: roughly 6.8 times trailing earnings and about 2.9 times forward earnings, the gap between the two reflecting expectations for higher earnings ahead. The business itself is reported as profitable, with a net margin near 28%, alongside revenue growth of about 159% over the comparison period. Price-to-book is negative, which happens when liabilities exceed assets on the balance sheet and makes that particular ratio uninformative here. Beta of 0.21 indicates the shares have historically moved largely independently of the broader market, so the price swings above are company-specific rather than inherited from the index.

Recent coverage is mostly about the company itself rather than the wider drug sector. The most recent items, from early 2026, focus on LINZESS net pricing being framed as a growth driver and on the stock's position among low-priced names with earnings momentum; one broader market wrap from January mentions the sector only in passing. Further back, the flow is more mixed: an April 2025 report of an FDA request for an additional trial on a gastrointestinal drug, which coincided with a sharp price decline, and 2024 items covering quarterly results that fell short of estimates. Taken together, the news history tracks a single-product commercial story and its pipeline decisions rather than industry-wide developments.

## About Ironwood Pharmaceuticals, Inc. - Class A

Ironwood Pharmaceuticals is a biotechnology company focused on treatments for gastrointestinal and rare diseases. Its commercial product is linaclotide, a guanylate cyclase type-C agonist sold as LINZESS in the United States and CONSTELLA in other markets, approved for adults with irritable bowel syndrome with constipation or chronic idiopathic constipation and for pediatric patients with functional constipation. Linaclotide is developed and commercialized through partnerships with AbbVie, AstraZeneca, and Astellas Pharma covering different territories.

The company's pipeline includes apraglutide, a long-acting synthetic analog of glucagon-like peptide-2 studied in short bowel syndrome with intestinal failure in patients dependent on parenteral support, and in acute graft-versus-host disease; and IW-3300, another guanylate cyclase type-C agonist aimed at visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis. Ironwood was incorporated in 1998 as Microbia and adopted its current name in 2008. It is headquartered in Boston, Massachusetts.

## Company profile

- Symbol: IRWD
- Exchange: NASDAQ
- Security type: Stock
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Composite sentiment: positive (19 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $696.31M |
| Enterprise value | $1.07B |
| Trailing P/E | 6.82 |
| Forward P/E | 2.94 |
| Price to book | -3.21 |
| Price to sales | 1.93 |
| Beta | 0.21 |
| Net margin | 28.26% |
| Revenue growth | 1.59% |
| 52-week high | $5.78 |
| 52-week low | $0.72 |
| Average volume | 2.46M |

## Related stocks

- [MNPR](https://synoptiv.com/stock/MNPR)
- [AURA](https://synoptiv.com/stock/AURA)
- [FTH](https://synoptiv.com/stock/FTH)
- [CLYM](https://synoptiv.com/stock/CLYM)
- [RIGL](https://synoptiv.com/stock/RIGL)
- [NVCT](https://synoptiv.com/stock/NVCT)
- [CTMX](https://synoptiv.com/stock/CTMX)
- [ACHV](https://synoptiv.com/stock/ACHV)
- [950160.KQ](https://synoptiv.com/stock/950160.KQ)

## Recent news

- [Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth](https://seekingalpha.com/article/4928110-buy-the-dip-2-top-undervalued-stocks-averaging-394-percent-forward-eps-growth) — Jul 31, 2026
- [Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call](https://www.businesswire.com/news/home/20260730260876/en/) — Jul 30, 2026
- [Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust](https://seekingalpha.com/article/4927672-ironwood-pharmaceuticals-one-trial-stands-between-bargain-and-bust) — Jul 30, 2026
- [Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal Failure](https://www.benzinga.com/news/26/07/60437227/ironwood-pharma-initiates-phase-3-stars-2-trial-apraglutide-short-bowel-syndrome-intestinal-failure) — Jul 14, 2026
- [Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients](https://www.businesswire.com/news/home/20260714515996/en/) — Jul 14, 2026
- [Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap](https://seekingalpha.com/article/4921696-ironwood-linzess-buys-time-but-apraglutides-rnpv-doesnt-close-gap) — Jul 13, 2026
- [BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?](https://finance.yahoo.com/markets/stocks/articles/biocryst-bcrx-surges-8-1-141400956.html) — Jul 8, 2026
- [4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues](https://finance.yahoo.com/markets/stocks/articles/4-defensive-stocks-refuge-tech-122500473.html) — Jul 8, 2026
- [Get insights into the top gainers and losers of Tuesday's after-hours session.](https://www.chartmill.com/news/TC/Chartmill-50715-Get-insights-into-the-top-gainers-and-losers-of-Tuesdays-after-hours-session) — Jul 7, 2026
- [12 Health Care Stocks Moving In Tuesday's After-Market Session](https://www.benzinga.com/trading-ideas/movers/26/07/60321330/12-health-care-stocks-moving-tuesday-s-after-market-session) — Jul 7, 2026

## Frequently asked questions

### What is the current market sentiment for IRWD?

As of Aug 2, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) carries positive (+19 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has IRWD stock been performing?

Ironwood Pharmaceuticals, Inc. - Class A last closed at $4.23, in the upper half of its 52-week range of $0.72–$5.78.

### What is IRWD's market cap and valuation?

Ironwood Pharmaceuticals, Inc. - Class A has a market capitalization of about $696.31M, a trailing P/E of 6.8.

### What sector is IRWD in, and who are its competitors?

Ironwood Pharmaceuticals, Inc. - Class A operates in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic. Comparable companies include MNPR, AURA, FTH, CLYM, RIGL.

### Where can I find a full analysis of IRWD?

The full IRWD report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/IRWD/v/1) (account and access required)